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MGMT Inhibition Restores ERα Functional Sensitivity to
Antiestrogen Therapy
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Maria-Lourdes M Caparas,1 Susan M Constantino,1 Nikita Shah,1,3 Cheryl H Baker,2
Kalkunte S Srivenugopal,5 Said Baidas,1,3 and Santhi D Konduri1,3
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Medicine, University of Central Florida, Orlando, Florida, United States of America; 3Florida State University, College of Medicine,
Orlando, Florida, United States of America; 4Aurora Advanced Healthcare, Milwaukee, Wisconsin, United States of America; and
5
Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America

Antiestrogen therapy resistance remains a huge stumbling block in the treatment of breast cancer. We have found significant
elevation of O6 methylguanine DNA methyl transferase (MGMT) expression in a small sample of consecutive patients who have
failed tamoxifen treatment. Here, we show that tamoxifen resistance is accompanied by upregulation of MGMT. Further we show
that administration of the MGMT inhibitor, O6-benzylguanine (BG), at nontoxic doses, leads to restoration of a favorable estrogen
receptor alpha (ERα) phosphorylation phenotype (high p-ERα Ser167/low p-ERα Ser118), which has been reported to correlate with
sensitivity to endocrine therapy and improved survival. We also show BG to be a dual inhibitor of MGMT and ERα. In tamoxifenresistant breast cancer cells, BG alone or in combination with antiestrogen (tamoxifen [TAM]/ICI 182,780 [fulvestrant, Faslodex]) therapy enhances p53 upregulated modulator of apoptosis (PUMA) expression, cytochrome C release and poly (ADP-ribose) polymerase (PARP) cleavage, all indicative of apoptosis. In addition, BG increases the expression of p21cip1/waf1. We also show that BG,
alone or in combination therapy, curtails the growth of tamoxifen-resistant breast cancer in vitro and in vivo. In tamoxifen-resistant
MCF7 breast cancer xenografts, BG alone or in combination treatment causes significant delay in tumor growth. Immunohistochemistry confirms that BG increases p21cip1/waf1 and p-ERα Ser167 expression and inhibits MGMT, ERα, p-ERα Ser118 and ki-67 expression. Collectively, our results suggest that MGMT inhibition leads to growth inhibition of tamoxifen-resistant breast cancer in vitro
and in vivo and resensitizes tamoxifen-resistant breast cancer cells to antiestrogen therapy. These findings suggest that MGMT inhibition may provide a novel therapeutic strategy for overcoming antiestrogen resistance.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2012.00010

INTRODUCTION
Targeting the estrogen signaling pathway dramatically improves the longterm disease-free and overall survival in
women with estrogen receptor-positive
breast cancer. Roughly, 70% of human
breast tumors express significant levels
of estrogen receptor alpha (ERα) (1),

making antiestrogen therapy an important therapeutic modality in breast cancer treatment (2–4). One fourth of
ER+/PR+ tumors, two-thirds of ER+/PR–
and approximately one-half of ER–/PR+
tumors fail to respond to tamoxifen altogether or develop early resistance (5).
There is extensive data supporting vari-
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ous correlations between ERα phosphorylation patterns and sensitivity to antiestrogen therapy and clinical indicators of
treatment response (delayed disease progression/improved survival) (6–10). ERα
phosphorylation of serine residues in the
activation domain function 1 (AF-1)
leads to enhanced ERα-driven transcription via modulation of coactivators recruitment. There are different degrees of
Ser118 phosphorylation which correlate
with different ERα functional states.
Functional ERα correlates with low
Ser118 phosphorylation similar to Ser118
phosphorylation pattern encountered
with estradiol binding which is mitogenactivated protein kinase (MAPK) independent (11). Endocrine therapy resistant
ERα is associated with high Ser 118
phosphorylation which is estradiol independent and has been linked to MAPK
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activation via Her2-MAPK pathwaydriven phosphorylation of AIB1 (amplified in breast cancer 1) which is a coactivator of ERα and, when overexpressed,
is involved in both de novo and acquired
tamoxifen resistance (12–14).
High ERα Ser167 phosphorylation,
which seems to be estrogen dependent
(7–9,15), has been linked to better response to endocrine therapy and improved survival. Furthermore, recent
data suggests that when various Ser118
and Ser167 phosphorylation states are
compared, a combination phenotype
with low Ser118 and high Ser167 phosphorylation correlates with best clinical
indicators of response (disease free survival and overall survival) (7).
Tamoxifen is a synthetic estrogen receptor ligand that competitively inhibits estrogen binding to estrogen receptors and, depending on the target tissue, has mixed
agonist and antagonist activity. This has
led to the redesignation of this class of
compounds from antiestrogens to selective
estrogen receptor modulators (SERMs)
(16). SERMs have produced marked reductions in breast tumor size (17,18) and
have increased patient survival (19,20).
Compared with cytotoxic chemotherapy,
antiestrogens are associated with minor
toxicities and are well tolerated (21), but
resistance remains a significant clinical
problem (4,19,20,22–30). Tamoxifen has
been shown to have only modest activity
against other malignancies, such as
hepatocellular, colorectal, ovarian, pancreatic, renal cell carcinomas, gliomas and
melanomas (22). A number of hypotheses
have been proposed to explain tamoxifen
resistance, including altering the pharmacology of tamoxifen, modification of the
ER structure and function, cross-talk between the ERα and growth factor signaling pathways and altered expression of
coactivators and/or corepressors
(12–14,31–34).
MGMT has been studied mostly as a
DNA repair enzyme involved in resistance to alkylating agents. MGMT repairs
the mutagenic and cytotoxic interstrand
DNA crosslinks resulting after alkylating
agent attack at the nucleophilic O6-

position of guanine. MGMT is constitutively expressed in normal cells and tissues (35). In breast cancer, MGMT gene
expression is uniformly elevated (36) and
could be up to four times higher than in
normal breast tissue (37,38). The free base
BG is a pseudosubstrate for MGMT and
can effectively and rapidly deplete
MGMT in both cell culture and human
tissues. Because clinically used anticancer
methylating and chloroethylating agents
generate O6-guanine alkylations, depletion of MGMT by BG greatly increases
the cytotoxicity of alkylating agents
(39–41). BG is not incorporated into DNA
of living cells. BG reacts directly with
both cytoplasmic and nuclear MGMT. BG
binds MGMT and covalently transfers its
benzyl moiety to the MGMT cysteine active site (42) leading to degradation of the
MGMT complex after each reaction. The
focus of the previous BG clinical studies,
resulting in MGMT suppression, was to
find alternatives to enhance alkylating/
cytotoxic drug treatment.
It also has been suggested that MGMT
has other (nonrepair) functions, as it has
been reported to correlate with vascular
endothelial growth factor receptors
(VEGFRs) expression in vitro (43) and
possibly play a role in integrating DNA
damage/repair related signals with replication, cell cycle progression and genomic stability (44,45).
There is an inverse correlation between
the levels of MGMT and p53 tumor suppressor protein (46), where wild-type p53
suppresses transcription of MGMT expression (47) by direct binding to the
MGMT promoter (48). Unfortunately p53
is often inactivated or suppressed in cancers and restoration of p53 activity remains essential to the success of some
treatments.
Our previous data shows that ERα uses
a dual strategy to promote abnormal cellular proliferation in breast cancer: repressing the transcription of p53-responsive
genes and enhancing the transcription of
ERE-containing proproliferative genes
(49). To date, the potential mutual interrelationship between MGMT and ERα (and
the link to p53) has not been explored in
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drug- (tamoxifen) resistant breast tumors.
The goal of this study is to describe a
novel, nonrepair (p53 dependent) MGMT
function relative to modulation of ERα
and evaluate its potential as an alternative to circumvent antiestrogen therapy
resistance.
MATERIALS AND METHODS
Ethics Statement
Human tissue samples for MGMT immunoassays were used with the approval
of MD Anderson Cancer Center Orlando
Oncology Institutional Review Board
(IRB) after each patient was consented
under IRB protocol no 10.003.01, titled
“O6 Methylguanine DNA Methyl Transferase (MGMT) and Tamoxifen Resistance
in Patients with Breast Cancer: Study of
correlation between clinical resistance
and tissue expression of MGMT and
serum markers.” The Cancer Research Institute, MD Anderson Cancer Center Orlando, Orlando, Florida, USA was approved by the American Association for
Accreditation of Laboratory Animal Care
(AAALAC) in accordance with current
regulations and standards of the United
States Department of Agriculture, United
States Department of Health and Human
Services, and the National Institutes of
Health (NIH). Animal studies were performed in the specific pathogen-free
(SPF) animal facility of the Cancer Research Institute of MD Anderson Cancer
Center Orlando. Animal experiments
were performed with the approval of MD
Anderson Cancer Center Orlando Institutional Animal Care and Use Committee
(IACUC; approval protocol no. 09.05.01).
Cell Culture
All tamoxifen sensitive breast cancer
cell lines were purchased from the American Tissue Culture Collection (ATCC;
Manassas, VA, USA). We have developed
two separate lines of tamoxifen-resistant
breast cancer cells as described by others
(50,51), using MCF7 as parental ERpositive breast cancer cell line. Breast
cancer cell lines MCF7 (and tamoxifenresistant MCF7), BT474, MDA MB468
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were grown in Dulbecco's modified
Eagle medium (DMEM); ZR75 and
HCC38 cells were grown in RPMI 1640;
SKBR3 cells were grown in McCoy’s 5A
medium. All the media were supplemented with 10% fetal bovine serum
and 1% penicillin-streptomycin (GIBCO,
Invitrogen Corporation, NY, USA). Adherent monolayer cultures were maintained at 37°C containing 5% CO2. Normal breast epithelial cells MCF10A were
grown in MEGM media supplemented
with bullet kit and 100 ng/mL cholera
toxin (catalog no. CC-3150; Lonza Inc.
Allendale, NJ, USA). HTB128 was grown
in Leibovitz’s L15 medium, with
2 mmol/L L-glutamine supplemented
with 10 mcg/mL insulin, 10 mcg/mL
glutathione and 15% fetal bovine serum.
Antibodies and Drugs
p53 (#sc-126), ERα (#sc-543) normal
mouse IgG and HRP (#sc-2025; #sc-2748),
phospho ERα Y537 (#sc-32827) antibodies
were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA. USA).
MGMT (#MAB16200) and ki-67
(#MAB4190) antibodies were purchased
from Millipore (now EMD Millipore, Billerica, MA, USA). p21 (#2946), cleaved
poly (ADP-ribose) polymerase (PARP)
(#9546), cytochrome C (#4272), p53 upregulated modulator of apoptosis
(PUMA) (#4976), phospho ERα Ser167
(#2514S) and phospho ERα Ser104/106
(#2517) were purchased from Cell Signaling (Cell Signaling Technology Inc., Danvers, MA, USA). β-Actin (#A2066) antibody was purchased from Sigma-Aldrich
(St. Louis, MO, USA). Phospho ERα
Ser118 (#ab32396) was purchased from
Abcam (Cambridge, MA, USA). O6-benzylguanine (BG; MGMT Blocker) and 4OH tamoxifen (TAM) was purchased
from Sigma-Aldrich. ICI 182,780 (fulvestrant, Faslodex) was purchased from
Tocris (Ellisville, MO, USA). BG, TAM
and ICI initially were dissolved in ethanol
and subsequent dilutions were made with
tissue culture media. Equal amounts of
ethanol were used in tissue culture media
for untreated controls to amount to a concentration of <0.0005%.

Western Blotting
Normal breast epithelial cells
(MCF10A) and human breast cancer cell
lines (MCF7, ZR75, MDA MB468, SKBR3,
HTB128, BT474 and HCC38) were plated
(1 × 106) in 10 cm2 petri dishes. Media
was removed 48 h later, cells were
washed twice with 1 × PBS and lysates
were prepared using 1 × Laemmli buffer
(Bio-Rad, Hercules, CA, USA), total proteins were estimated using BCA Protein
Assay Kit (Pierce, Rockford, IL USA) and
Western blot analysis was performed.
Similarly, MCF7 breast cancer cells and
tamoxifen-resistant MCF7 breast cancer
cells were plated (1 × 106) in 10 cm2 petri
dishes and 48 h later cells were washed
twice with 1 × PBS and lysed using 1 ×
Laemmli buffer and total proteins were
estimated before Western blot analysis
was performed. In another set of experiments, tamoxifen-resistant breast cancer
MCF7 cells were plated (5 × 105) for 24 h
and further transfected with nontarget
(NT) small interfering RNA (siRNA)
(100 nmol/L) and MGMT siRNA
(100 nmol/L) for 72 h before Western blot
analysis. Human tamoxifen-resistant
breast cancer MCF7 cells were plated (1 ×
106) in 10 cm2 petri dishes and the next
day were treated with BG (140 μmol/L)
for 24 h before treatment with 4-OH tamoxifen (1 μmol/L) or ICI (1 μmol/L) for
another 48 h before cells were harvested
and washed twice with 1 × PBS and
lysates were made using 1 × Laemmli
buffer before proteins were separated on
10% SDS-PAGE gels, transferred to nitrocellulose membranes followed by standard procedure (52–54). Tamoxifenresistant MCF7 breast cancer cells were
plated (1 × 106) in 10 cm2 petri dishes and
the next day cells were treated with different concentrations of BG for 48 h before cells were harvested and washed
with 1 × PBS twice and proteins were isolated using 1 × Laemmli buffer for Western blot analysis. For phosphorylation experiments, 17β-estradiol (10 nmol/L) was
added for 30 min prior to harvesting the
cells. In another set of experiments we
have investigated the expression of
cleaved PARP in tamoxifen-resistant

MCF7 breast cancer cells after TAM, ICI,
BG alone or combination treatments.
MCF7 cells (1 × 106) were plated and 24 h
later cells were treated with BG
(140 μmol/L = IC50) for 24 h before treatment with TAM (1 μmol/L) or ICI
(1 μmol/L) for 48 h. Cells were harvested
and Western blot analysis was performed.
Growth Inhibition ATP Assay
Tamoxifen-resistant MCF7 breast cancer cells were plated (2 × 103/well) in
96-well plates (Lonza, Rockland, ME,
USA) in DMEM, supplemented with 10%
FBS, and 24 h later cells were treated
with different concentrations of BG
(10–200 μmol/L) and harvested 48 h or
72 h after treatment. Cell viability was
determined by measuring the amount of
adenosine-5′-triphosphate (ATP) present.
The ATP was measured using the Cell
Titer-Glo Luminescent Cell Viability
Assay (Promega, Madison, WI, USA).
The detection of luminescence (RLU)
was measured by Optima Fluor Star Luminometer (BMG Lab Tech, Cary, NC,
USA). In another set of experiments,
tamoxifen-resistant MCF7 breast cancer
cells were treated with BG for 48 h before
TAM (1 μmol/L) or ICI (1 μmol/L) were
added for 24 h prior to ATP assay. In another set of experiments, tamoxifenresistant MCF7 breast cancer cells were
transfected with NT siRNA and MGMT
siRNA (100 nmol/L) and 72 h after transfection, ATP assay was performed. In another set of experiments we investigated
the effect of MGMT siRNA in the presence or absence of BG (50 or 140 μmol/L)
on tamoxifen-resistant MCF7 breast cancer cells. MCF7 cells (5 × 103) were plated
for 24 h before transfection with NT
siRNA (1–5 nmol/L) or MGMT siRNA
(1–5 nmol/L) in presence or absence of
BG. Cells were treated with BG (50 μmol/L
or 140 μmol/L) 24 h after transfection for
48 h before ATP assays were performed.
In another set of experiments, we investigated the effect of BG (50 μmol/L or
140 μmol/L) either alone or in combination with TAM/ICI on tamoxifenresistant MCF7 cells. Tamoxifen-resistant
MCF7 cells (5 × 103) were plated and,
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24 h later, cells were treated with BG
(50 μmol/L or 140 μmol/L) for 24 h before further treatment with tamoxifen
(1 μmol/L) or ICI (1 μmol/L) for another
48 h before harvest and ATP assay.
Quantitative Real-Time PCR
For qRT-PCR, tamoxifen-resistant
MCF7 breast cancer cells were plated (5 ×
105) and, the next day, cells were transfected with NT siRNA (20 μmol/L) or
p53 siRNA (20 μmol/L) for 48 h before
BG (140 μmol/L) was added for another
24 h before cells were harvested. These
cells were lysed using TRIzol reagent (Invitrogen). Total RNA was isolated using
the Qiagen columns (Qiagen, Valencia,
CA, USA) and reverse transcribed using
SuperScript First Strand Synthesis System
for RT-PCR (Cat. No. 12371-019). Quantitative real-time PCR (qRT-PCR) was performed using ABI 7300 sequence detection system (Applied Biosystems,
Carlsbad, CA, USA). TaqMan gene expression assays for p53 (Hs00153349_m1),
p21 (Hs00355782_m1) and β-actin
(4333762F) were purchased from Applied
Biosystems. The relative mRNA levels of
p53 and p21 were calculated using the
ΔΔ Ct method, with the β-actin mRNA as
an endogenous control.
Reporter Assay
For reporter assays, tamoxifen-resistant MCF7 cells (5 × 104) were seeded in
12-well plates and transfected with p21luc construct (55) for 6 h before being
treated with or without BG (140 μmol/L)
for 24 h before harvest and lysis. Luciferase activity was measured using a
dual luciferase reporter assay system following the manufacturer’s protocol
(Promega Corporation, Madison, WI,
USA). Lipofectamine 2000 (Invitrogen)
was used for transfection according to
the manufacturer’s protocol.
ChIP Assay
Tamoxifen-resistant MCF7 breast cancer
cells were plated (2 × 105) and 24 h later
transfected with both NT and p53 siRNA
(20 μmol/L each) for 48 h before being
treated with or without BG (140 μmol/L)

for another 24 h prior to harvest for chromatin immunoprecipitation assays (ChIP).
ChIP assays were performed as per the
manufacturer’s instructions (Upstate, Lake
Placid, NY, USA) with minor modifications (49,52,53,56,57). Cell lysates (400 μL)
were sonicated 25 times, alternating each
10 sec pulse with 20 sec gaps (Misonix
Inc., Farmingdale, NY, USA). After centrifugation, 50 μL of the supernatant was
used for checking DNA fragmentation as
well as input and the remaining 350 μL
was used for chromatin immunoprecipitation. The following antibody and primers
were used for ChIP assay (56): p53 antibody (DO-1) was purchased from Santa
Cruz Biotechnology (ChIP grade): p21
(5′ site) forward: GCTGT GGCTC TGATT
GGCTT T; p21 (5′ site) reverse: ACAGG
CAGCC CAAGG ACAAA; p21 (3′ site)
forward: CATCC CCACA GCAGA
GGAGA A; and p21 (3′ site) reverse:
ACCCA GGCTT GGAGC AGCTA.
MGMT Activity Assay
Exponentially growing tamoxifenresistant MCF7 cells were treated with BG
50 or 140 μmol/L for 24 h before TAM or
ICI were added for another 48 h. Cells
were trypsinized and washed with Trisbuffered saline (TBS; pH 8.0). Cell-free extracts were prepared by sonication in
MGMT assay buffer containing 40 mm
Tris-hydrochloric acid (Tris-HCl) (pH 8.0),
5% glycerol, 1 mm ethylenediaminetetraacetic acid (EDTA), 0.5 mm dithiothreitol (DTT), 50 μmol/L spermidine and
1 mmol/L phenylmethylsulfonyl fluoride
(PMSF) followed by centrifugation at
10,000g for 10 min. The substrate DNA enriched in O6-methylguanine was prepared
by using [methyl-3H] methylnitrosourea
(60 Ci/mmol; GE Healthcare, Pittsburgh,
PA ,USA) according to Myrnes et al. (58).
MGMT activity was determined by quantitating the transfer of the 3H-labeled
methyl group from the O6 position of guanine in the DNA to the MGMT protein
(59). Briefly, cell extracts (50–200 μg of
protein) were supplemented with 2 μg of
DNA substrate (~10,000 cpm) and incubated at 37°C for 30 min, after which the
DNA was hydrolyzed in trichloroacetic
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acid at 80°C for 30 min. The protein precipitates were collected on glass fiber filters, washed with 5% trichloroacetic acid
(TCA) and ethanol, solubilized and the radioactivity was counted.
Flow Cytometry Analysis
We performed fluorescence-activated
cell sorting (FACS) to further evaluate cell
cycle distribution changes mediated by
BG alone or in combination with
TAM/ICI. Tamoxifen-resistant MCF7 cells
(1 × 106) were plated and grown to acclimate for 24 h followed by treatment with
BG for 24 h before treatment with
TAM/ICI for another 48 h under the
following conditions: Control, TAM
(1 μmol/L), ICI (1 μmol/L), BG
(140 μmol/L), BG (140 μmol/L) + TAM
(1 μmol/L) and BG (140 μmol/L) + ICI
(1 μmol/L). Cells were harvested and
washed twice in PBS before they were incubated for 30 min in propidium iodine
solution. The cell cycle distribution was
determined by flow cytometry using BD
FACS Calibur (BD Biosciences, San Jose,
CA, USA) and analyzed using FlowJo
(Tree Star, Ashland, OR, USA). The
Dean/Jett/Fox cell cycle analysis module
was used in FlowJo to determine the distribution of cells throughout the cell cycle.
Orthotopic Injection of Breast Cancer
Cells in Athymic Nude Mice
Female ovarectomized athymic nude
mice were purchased from Harlan (Indianapolis, IN, USA). The mice were
housed and maintained in specific pathogen-free conditions. The mice were used
when they were 6 to 8 wks of age, in accordance with institutional guidelines as
stipulated by the IACUC. To develop tumors, tamoxifen-resistant MCF7 luc cells
(tamoxifen-resistant MCF7 cells were
tagged with luciferase expression vector
to monitor tumor growth by Kodak Imaging System, Rochester, NY, USA) were
harvested from subconfluent cultures by a
brief exposure to 0.05% trypsin and 0.02%
EDTA. Trypsinization was stopped with a
medium containing 10% fetal bovine
serum as the cells were washed once in a
serum-free medium and resuspended in
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Hanks balanced salt solution (HBSS).
Only suspensions consisting of single cells
with >90% viability were used for injections. A 1.7 mg time release β-estradiol
pellet (Innovative Research of America,
Sarasota, FL, USA) was implanted over
the right shoulder of each mouse and 24 h
later MCF7 luc (7 × 106) cells were injected
into the mammary fat pad.
Therapy of Established Human
Tamoxifen-Resistant MCF7 Breast
Cancer Cells Growing in the
Mammary Fat Pad of Nude Mice
The mice were randomized into six
groups (n = 10), 10 d after injection of
tamoxifen-resistant MCF7 cells into the
mammary fat pad, as follows: (a) daily
(Monday through Friday) intraperitoneal
(IP) injections of 1 × PBS (for control
group); (b) daily IP injections of BG; (c)
twice weekly injections of tamoxifen
(1 mg/kg); (d) twice weekly injections of
ICI (1 mg/kg); (e) combination therapy of
BG (10 mg/kg, daily) and tamoxifen
(twice weekly, 1 mg/kg); and (f) combination therapy of BG (10 mg/kg, daily) and
ICI (twice weekly, 1 mg/kg). In previous
studies in our laboratory, we have determined that tamoxifen and ICI concentrations of 1 mg/kg twice/week IP injections
were well tolerated by mice (data not
shown). Furthermore, BG at 10 mg/kg
also was well tolerated by mice (data not
shown). Treatments were continued for
6 wks, after which the mice were euthanized and subjected to necropsy. Tumor
volumes were calculated using the following formula: (length)2 × (width)/2.
Histological Studies
For immunohistochemistry and histologic staining, paraffin embedded tissues
were used to detect protein expression of
MGMT, ERα, p53, p21, phospho ERα
Ser167, phospho ERα Ser118 and ki-67.
Sections (4–6 μm thick) were mounted on
positively charged superfrost slides (Fischer Scientific, Houston, TX, USA) and
dried overnight. Sections were deparaffinized in xylene and subsequently
treated with a graded series of alcohol
(100%, 95%, and 80% ethanol [vol/vol] in

deionized H2O) and re-hydrated in
deionized H2O and PBS (pH 7.5). Antigen
retrieval was achieved by placing slides
in 100°C 0.1 mol/L citrate buffer (pH 6.0)
for 10 min, followed by 30 min of bench
top cooling. For the phosphorylated ERα,
antigen retrieval required placing slides
in 0.1 mol/L citrate buffer (pH 6.0) in a
water bath maintained at 98°C for 30 min
followed by bench top cooling for 45 min.
Slides were washed with PBS that contained 0.1% triton and 0.1% BSA. Endogenous peroxidase was blocked with
3% hydrogen peroxide in PBS, while nonspecific binding was blocked with 10%
normal horse serum (10% goat serum for
phosphorylated ERα Ser167) and 2% BSA
in PBS. The slides were incubated at 4°C
overnight in a moist chamber with one of
the following: 1) monoclonal mouse antiMGMT antibody (Invitrogen; #35-700;
10 μg/mL); or 2) monoclonal mouse antip53 antibody (Santa Cruz Biotechnology;
#sc126; 1:50 dilution); or 3) mouse
anti-ki-67 antibody (EMD Millipore;
#MAB 4190; 1:50 dilution); or 4) monoclonal mouse anti-p21 (Cell Signaling;
#2946; 1:100 dilution); or 5) monoclonal
mouse anti-phosphorylated ERα Ser118
(Cell Signaling; #2511; 1:100 dilution); or
6) polyclonal rabbit anti-phosphorylated
ERα Ser167 (Abcam; #ab31478; 1:100 dilution). Slides were washed with PBS that
contained 0.1% triton and 0.1% BSA.
After 1 h incubation at room temperature
with a biotinylated horse anti-mouse
IgG/streptavidin complex (VWR, USA,
PA; #PI32052) or goat anti-rabbit
IgG/streptavidin complex (VWR, PA,
USA; #8010), a positive reaction was visualized by incubating the slides with
stable 3,3′-diaminobenzidine (Invitrogen)
for 8–10 min. Counterstaining was
achieved by rinsing the sections with two
changes of tap water, placing them in
Gill’s filtered hematoxylin (EMD Chemicals Inc., Gibbstown, NJ, USA) for 10
min, followed by successive dips into tap
water, acid alcohol (EMD Chemicals), tap
water, lithium carbonate (EMD Chemicals) and tap water. For ERα detection,
antigen retrieval was achieved by placing
slides in 100°C 0.1 mol/L citrate buffer

(pH 6.0) for 30 min followed by 1 h of
bench top cooling. Slides were washed
with PBS that contained 0.2% triton and
0.1% BSA. Endogenous peroxidase was
blocked with 3% hydrogen peroxide in
PBS, while nonspecific binding was
blocked with 10% normal goat serum and
2% BSA in PBS. The slides were incubated
at 4°C overnight in a moist chamber with
monoclonal rabbit anti-ERα antibody
(EMD Millipore; #04-227; 1:50 dilution).
Slides were washed with PBS that contained 0.2% triton and 0.1% BSA. After a
1 h incubation with a biotinylated goat
anti rabbit IgG/streptavidin complex
(VWR; #8010) a positive reaction was visualized by incubating the slides with stable 3,3′-diaminobenzidine (Invitrogen) for
15 min. Counterstaining was achieved by
rinsing the sections with two changes of
tap water, placing them in Gill’s filtered
hematoxylin (EMD Chemicals) for 15 min,
followed by successive dips into tap water,
acid alcohol (EMD Chemicals), tap water,
lithium carbonate (EMD Chemicals) and
tap water. All slides were mounted with
Crystal Mount (Fischer Scientific). Control samples exposed to secondary antibody alone showed no specific staining.
The images were analyzed by ImageJ
(NIH, Betheseda, MD, USA; http://
rsbweb.nih.gov/ij/) with MGMT, ERα,
phosphorylated ERα Ser118, phosphorylated ERαSer167, p53, p21 and ki-67 expressions quantified by the ImmunoRatio
plugin (60). Results were reported as
mean ± SD as for each condition five contiguous slides were generated and
analyzed.
Statistical Analysis
Experiments were performed in triplicates and data presented as mean ± SD.
Statistical analysis was done using Student
t test, assuming equal variance, and each
p value was calculated based on twotailed test. A p value of <0.05 was considered statistically significant. P values are
reported using a star system as follows:
*P < 0.05; **P < 0.005 and ***P < 0.0005.
All supplementary materials are available
online at www.molmed.org.
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samples of the metastatic tumors evaluated were from different organ sites
(bone, brain, chest wall, lung and liver).
MGMT expression levels in the original
breast cancer tissue and the metastatic
site were quantified as explained under
Materials and Methods and compared
for each patient. In the post–tamoxifentreated breast cancer patients, MGMT expression levels were higher in the
metastatic tissue when compared with
the original breast cancer tissue (prior to
tamoxifen treatment). At the time of tamoxifen failure when metastatic sites
were found, MGMT expression was
found to be increased by 14% in the
brain metastases patient (patient 2), 21%
in the chest wall metastases patient (patient 3), 23% in the liver metastases patient (patient 5), 30% in the lung metastases patient (patient 4) and 59% in the
bone metastases patient (patient 1) when
compared with the MGMT expression in
the breast cancer tissue at the time of initial diagnosis (Figure 1).

Figure 1. Immunohistochemistry analyses on breast cancer patient tissue samples. Tumor
tissue was derived from the breast cancer patient samples before and after tamoxifen.
The sections were immunostained for expression of MGMT. MGMT expression is higher in
post–tamoxifen-treated samples compared with pre tamoxifen treated samples. Representative samples (40×) are shown.

RESULTS
MGMT Expression Levels from
Tissue Samples in Pre– and
Post–Tamoxifen-Treated Breast
Cancer Patients
We have found five consecutive patients who had failed tamoxifen and had
to have a confirmatory biopsy or surgical

resection of symptomatic lesions at the
time of progression and had been enrolled in our correlative MD Anderson
Cancer Center Orlando IRB–approved
protocol no. 10.003.01 (see Ethics Statement section for protocol title). Each
sample used in this study had patient
consent for both study and publication
purposes. The post–tamoxifen-treated
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MGMT is Highly Expressed in Breast
Cancer Cells and It Is Further
Increased in Tamoxifen-Resistant
Breast Cancer Cells
We have screened both normal breast
epithelial cells (MCF10A) and several
breast cancer cell lines (MCF7, ZR75,
MDA MB468, SKBR3, HTB128, BT474,
HCC38) for MGMT expression. Consistent with previous observations (35–38),
MGMT levels were markedly higher in
breast cancer cell lines than in normal
breast epithelial cells (Figure 2A). When
compared with the normal epithelial
breast cells, MGMT expression was 1- to
2-fold higher (P < 0.005) in the both
ER+/wild type p53 MCF7 and ZR75
breast cancer cell lines (Figure 2A).
MGMT expression was 1.5- to 2.5-fold
higher (P < 0.005) in the highly metastatic, ER-/mutated p53 MDA MB468 and
in the triple negative/mutated p53
HCC38 when compared with the normal
epithelial breast cells (Figure 2A).
MGMT expression was 0.15–0.3-fold
higher (P < 0.005) in the ER-/mutated
p53/Her2neu positive SKBR3 and the
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Figure 2. MGMT protein expression in breast cancer cells. MGMT expression was determined by Western blot analysis. (A) MGMT expression in
normal epithelial breast cells was compared with several breast cancer cell lines. Breast cancer cell lines showed higher expression of MGMT
compared with normal breast epithelial cells (MCF10A). (B) Tamoxifen-resistant MCF7 breast cancer cells show significantly increased MGMT expression compared with MCF7 parental cells (B). (C) Effect of MGMT inhibition by specific siRNA was determined on tamoxifen-resistant MCF7
breast cancer cell growth by ATP assay. Tamoxifen-resistant MCF7 cells were transfected with NT (nontarget) and MGMT siRNA (MGMT KD); and
ATP assays were performed after 72-h treatment. MGMT-silenced cells showed more than 50% decreased luminescence when compared with
NT cells. (D, E) Inhibition of MGMT by siRNA led to inhibition of ERα expression and increased p53 expression in wt p53 cells (tamoxifen-resistant
MCF7 cells) and there was no change in the mild ERα positive, mutated p53, low MGMT expressing BT474 cells.
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Figure 3. Benzylguanine inhibits tamoxifen-resistant breast cancer growth, induces cell cycle
arrest and apoptosis and sensitizes resistant breast cancer cells to antiestrogen therapy. Tamoxifen-resistant MCF7 breast cancer cells were treated with different concentrations of BG
and ATP growth inhibition assay was performed after 48 h (n) and 72 h (n). (A) BG led to significant growth inhibition in a dose-dependent manner (BG IC50 = 140 μmol/L, at 48 h). (B) Tamoxifen-resistant MCF7 cells were treated with BG for 24 h and TAM or ICI was added for another 48 h before growth inhibition ATP assay was performed. BG had a direct inhibitory
effect and further enhanced the activity of TAM/ICI. (C) Tamoxifen-resistant MCF7 breast
cancer cells were treated in the presence or absence of BG (IC50 = 140 μmol/L) and 24 h
later TAM (1 μmol/L) or ICI (1 μmol/L) was added for 48 h. p53 expression was not changed
significantly, MGMT was decreased significantly by 90% in the BG- and BG + TAM/ICI-treated
cells. ERα expression was increased by TAM and decreased by BG or BG + TAM/ICI. (Control
[ ]; 4-OH TAM [ ]; ICI [ ]; BG [ ]; 4-OH TAM + BG [ ]; ICI + BG [ ]). (D) Tamoxifen-resistant
MCF7 cells were treated with different concentrations of BG and MGMT, p21, cytochrome C
expression was determined by Western blot analysis. BG in a dose-dependent manner led to
induction of p21 expression, release of cytochrome C and inhibition of MGMT. (Control [ ];
BG 40 μmol/L [ ]; BG 60 μmol/L [ ];BG 80 μmol/L [ ];BG 100 μmol/L [ ];BG 120 μmol/L [ ];BG
140 μmol/L [ ];BG 160 μmol/L [ ]). (E) Cytochrome C, PUMA and p21 correlative expression
was determined by Western blot analysis in BG (140 μmol/L) and BG combination therapy
showing increased release of apoptosis mediators in the BG and BG combination therapy
conditions. (Control [ ]; 4-OH TAM [ ]; ICI [ ]; BG [ ]; 4-OHTAM + BG [ ]; ICI + BG [ ]). (F) Tamoxifen-resistant MCF7 cells were treated with BG (140 μmol/L) for 24 h before either TAM or
ICI was added, for another 48 h before cells were harvested and cleaved PARP expression
was measured by Western blot. Cleaved PARP was increased by single agents (TAM or ICI or
BG) compared with control and it was increased further by combination therapy (TAM +
BG/ICI + BG). (Control [ ]; 4-OH TAM [ ]; ICI [ ]; BG [ ]; 4-OHTAM + BG [ ]; ICI + BG [ ]).
Continued

920 | BOBUSTUC ET AL. | MOL MED 18:913-929, 2012

mild ER+/mutated p53/strongly
Her2neu + BT474 (Figure 2A). MGMT expression was one-fold higher (P < 0.005)
in the mild ER+/mutated p53/Her2neu +
HTB128 when compared with normal
epithelial breast cells (Figure 2A).
We have developed two separate lines
of tamoxifen-resistant breast cancer cells
as described by others (50,51) using
MCF7 as parental ER+ breast cancer cell
line. Tamoxifen-resistant MCF7 breast
cancer cells showed further increase in
the MGMT expression, up to 1.6-fold
higher (P < 0.005) when compared with
parental MCF7 cells (Figure 2B). There is
more than 0.5-fold (P < 0.0005) growth
inhibition when MGMT expression is silenced by MGMT specific siRNA in
tamoxifen-resistant MCF7 cells (Figure 2C).
We also examined the role of p53 in
siRNA specific MGMT inhibition and its
correlation with ERα in both tamoxifenresistant MCF7 (wild type p53) breast
cancer cells and BT474 cells (mutant p53).
Silencing MGMT in tamoxifen-resistant
(wild type p53) MCF7 decreased ERα expression and increased p53 expression
(Figure 2D). For an MGMT expression
reduction of 0.9-fold there was a correlative ER expression reduction of 0.5-fold
and an increase in the p53 expression of
0.45-fold. On the other hand there is no
alteration in the expression of ERα and
p53 in mutant p53 BT474 cells (Figure 2E).
This suggests the essential role of p53 in
mediating the MGMT-induced ERα
regulatory/inhibitory effect.
Benzylguanine (BG) Promotes Cell
Cycle Arrest and Inhibits TamoxifenResistant Breast Cancer Growth in an
MGMT-Independent Manner
Tamoxifen-resistant MCF7 breast cancer cell growth was inhibited in a direct,
dose-dependent manner when treated
with BG for 48 and 72 h (Figure 3A). BG
alone had a marked growth inhibitory effect and at 48 h, 140 μmol/L led to 50%
growth inhibition (BG IC50 = 140 μmol/L,
at 48 h) (P < 0.005) (Figure 3B). ICI had
less than 20% growth inhibitory effect
and 4-OH TAM had no growth inhibitory effect on tamoxifen-resistant
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MCF7 breast cancer cells (Figure 3B).
The addition of antiestrogen therapy
TAM or ICI to BG enhanced the inhibitory effect to 70% when compared
with control cells, but only added
slightly over 20% increase when compared with the BG inhibitory effect (P <
0.005) (Figure 3B). Tamoxifen-resistant
breast cancer cells continued to remain
sensitive to 17β-estradiol (E2)
(10 nmol/L) and showed 15% growth
stimulation in the conditions of the experiment (Figure 3B). To evaluate the
role of MGMT inhibition in the BG-induced growth inhibition we have compared BG 50 μmol/L with 140 μmol/L
and have measured MGMT activity and
evaluated the growth inhibitory effect of
BG alone versus combination treatments
(BG + TAM/ICI). BG, alone, at 50
μmol/L has been reported to be sufficient to lead to G2/M arrest (cytostasis,
promoting cell death) when highly expressing wt-MGMT colon cancer cell
lines (HCT116 and HCT15) were tested
(45). We have used BG 50 μmol/L as a
reference for the lowest necessary and
potentially sufficient concentration
which could lead to MGMT depletion
without any other further actions. In our
system (tamoxifen-resistant MCF7 cells)
BG 50 μmol/L has led to almost 90%
suppression of MGMT activity (Supplementary Figure S1A), but did not lead to
cell growth inhibition (Supplementary
Figure S1B) and further addition of
TAM/ICI did not lead to any significant
cell growth inhibition either (Supplementary Figure S1C). Cell growth inhibition was seen with BG at 140 μmol/L
(IC50) and this was further increased by
the addition of TAM/ICI (Supplementary Figure S1C).
While BG 50 μmol/L did not lead to
any growth inhibition, BG140 μmol/L
(IC50) growth inhibitory activity was only
slightly higher than the growth inhibitory
effect of MGMT siRNA. Further, growth
inhibition obtained by cancellation of
MGMT activity by siRNA MGMT was not
enhanced further by the addition of BG
50 μmol/L. The addition of BG 140 μmol/L
(IC50) to siRNA MGMT leads to further

Figure 3. Continued.

growth inhibition (18%) (Supplementary
Figure S1B). BG (140 μmol/L) led to an increase in the G2/M phase of the cell cycle,
indicating a G2/M arrest. This was further
increased significantly by the addition of
tamoxifen/ICI to the BG-treated cells (Supplementary Figure S2).
Benzylguanine Modulates p53 DownStream Targeted Protein Expressions
We also have investigated the effect of
BG and combination therapy (BG +
TAM/ICI) on endogenous MGMT, p53
and ERα protein expression in tamoxifenresistant MCF7 cells. BG alone decreased
both MGMT and ERα expression. BG at
140 μmol/L (IC50) induced 90% MGMT inhibition which correlated with 30% ERα

inhibition (P < 0.005) (Figure 3C). Combination therapy (BG + TAM) led to a 25%
decrease in ERα expression (P < 0.005)
when compared with tamoxifen-resistant
MCF7 cells and 54% when compared with
tamoxifen-stimulated tamoxifen-resistant
MCF7 cells (Figure 3C) (P < 0.005). TAM
alone increased expression of ERα by 60%
when compared with ERα expression in
the tamoxifen-resistant MCF7 cells and BG
treatment reversed this TAM effect (Figure 3C) (P < 0.005). ERα expression was
decreased by 60% (P < 0.005) by ICI in tamoxifen-resistant MCF7 cells and there
was further enhancement of the ICI inhibitory effect when BG was added with
an additional 20% decrease (P < 0.005)
(Figure 3C). When compared with the BG-
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Figure 4. Benzylguanine enhances p53 recruitment to p21 promoter and induction of p21 is p53 dependent. (A) Tamoxifen-resistant MCF7
breast cancer cells were transfected with p21-luc construct and 6 h later treated with BG for 24 h. p21 transcriptional activity was increased significantly by BG. (B) Tamoxifen-resistant MCF7 cells were transfected with NT siRNA and p53 siRNA and 48 h later treated with
BG for another 24 h before harvest for ChIP assay. BG increased p53 recruitment to p21 promoter on both 5′ and 3′ sites—explaining why
the MGMT p53 mediated inhibition does not require increased p53 expression (Figure 3C). Silencing p53 by siRNA showed no p53 binding
to the p21 promoter. (C) Tamoxifen-resistant MCF7 cells were transfected with NT siRNA or p53 siRNA and 24 h later treated with BG for 48
h before cells were harvested and Western blot analysis was performed. BG increased p21 protein expression in tamoxifen-resistant MCF7
cells significantly. p21 protein expression was decreased significantly when p53 was silenced independent of BG presence. There was no
change in p53 expression in the presence or absence of BG. (p53 [n]; p21 [n]). (D) Tamoxifen-resistant MCF7 cells were transfected with
NT siRNA and p53 siRNA and 24 h later treated with BG for another 48 h before harvest for real time PCR, using total RNA. BG significantly
induced p21 transcription in tamoxifen-resistant MCF7 cells and p21 transcription was decreased significantly when p53 was silenced, independent of BG presence. (Control [ ]; BG [ ]; p53 KD [ ]; p53KD + BG [ ]).

mediated MGMT inhibitory effect, MGMT
expression was not further reduced significantly when combination therapy was
used (BG + TAM/ICI) at the BG concentration used (140 μmol/L = IC50). Intermediary dose BG (100 μmol/L) when
compared with combination treatment
(BG + TAM/ICI) reveals that combination
treatment leads to a further reduction of
MGMT expression, higher with ICI than
TAM (30% versus 23%) (data not shown).
The slight reduction in p53 expression by

ICI alone was reversed when BG was
added (Figure 3C).
We also have investigated the effect of
BG on cell cycle regulation and apoptosis
in tamoxifen-resistant MCF7 breast cancer
cells. BG significantly (P < 0.05) increased
in a dose dependent manner both Cyt C
and p21cip1/waf1 protein expression (Figure
3D), suggesting that BG has a proapoptotic effect. The BG dose-dependent increase in Cyt C and p21cip1/waf1 correlated
with a BG-induced dose-dependent
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MGMT inhibitory effect (Figure 3D).
PUMA expression was increased by BG
and was increased further by combination
therapy (BG + TAM/ICI) (Figure 3E). The
effect of the combination treatments (BG +
TAM/ICI) showed further statistically
significant (P < 0.005) enhanced expression of apoptotic mediators (Cyt C,
PUMA) when compared with BG alone
(Figure 3E). PARP cleavage was increased
significantly by BG when compared with
TAM- or ICI-treated cells, and was en-
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Table 1. BG inhibits tamoxifen-resistant breast tumor growth and sensitize resistant breast cancer cells to antiestrogen therapy.
Breast Tumors
Tumor volume (mm3)

Tumor weight (mg)
Treatment groupa
Control
TAM
ICI
BG
TAM + BG
ICI + BG

Body weight (g)

Tumor incidence

Mean ± SD

Range

Mean ± SD

Range

Mean ± SD

Range

10/10
10/10
10/10
10/10
10/10
10/10

260.6 ± 18.3
257.0 ± 20.5
248.0 ± 18.9
94.2b ± 33.3
32.5d ± 8.9
58.2f ± 16.9

237.0–294.0
234.6–301.2
227.7–289.9
30.3–144.6
18.3–45.6
31.8–78.9

254.8 ± 28.7
270.6 ± 25.5
241.5 ± 17.2
120.2c ± 27.1
62.0e ± 21.0
75.1g ± 14.4

223.2–316.5
240.6–331.5
220.8–270.3
76.2–175.8
19.2–96.6
46.8–97.5

26.31 ± 1
26.02 ± 1.23
25.74 ± 1.25
25.31 ± 1
25.21 ± 0.7
25.69 ± 1

25.2–27.4
23.2–27.2
23.4–27.3
23.9–26.8
24.2–26.4
24.3–26.8

Tamoxifen-resistant breast cancer cells (7 × 106) were injected into the breast of nude mice. Groups of mice were randomized 10 d later
and treated with twice weekly (Tuesday, Thursday) IP injections of tamoxifen or ICI (1 mg/kg), versus daily (Monday through Friday [M–F])
IP injections of BG (10 mg/kg) alone versus combination therapy which received twice weekly IP injections of tamoxifen or ICI and daily
BG (M–F) versus control group which received daily (M–F) 1 × PBS. All mice were euthanized on d 42. Tumor size and volume in mice
treated with BG alone and in combination with TAM/ICI were significantly smaller when compared with mice treated with TAM/ICI alone
or to the control group.
a
MCF7-luc human breast cancer cells (7 × 106) were injected into the mammary fat pad of female ovarectomized nude mice. After a
palpable tumor was formed, six groups of mice were treated: vehicle solution; TAM (1 mg/kg); ICI (1 mg/kg); BG (10 mg/kg); TAM + BG
and ICI + BG. All mice were euthanized on d 42.
b
P < 0.0001 (BG) compared with control and P < 0.0001 (BG) compared with TAM + BG ( d ) and ICI + BG ( f ).
c
P < 0.0001 (BG) compared with control and P < 0.0001 (BG) compared with TAM + BG ( g ) and ICI + BG ( e ).
d
P < 0.0001 (TAM + BG) compared with control and P < 0.0001 (TAM + BG) compared with TAM alone.
e
P < 0.0001 (TAM + BG) compared with control and P < 0.0001 (TAM + BG) compared with TAM alone.
f
P < 0.0001 (ICI + BG) compared with control and P < 0.0001 (ICI + BG) compared with ICI alone.
g
P < 0.0001 (ICI + BG) compared with control and P < 0.0001 (ICI + BG) compared with ICI alone; .

hanced further by combination therapy
(Figure 3F). This data suggests that BG
promotes cell cycle arrest and can induce
apoptosis via modulation of p53 function.
Benzylguanine Enhances p21cip1/waf1
Transcriptional Activity in TamoxifenResistant Breast Cancer Cells
BG effect on p53 function via its downstream cell cycle regulator p21cip1/waf1 was
evaluated by luciferase reporter assays.
Tamoxifen-resistant MCF7 breast cancer
cells were transfected with a p21 luc promoter construct and, in the presence of
BG, revealed a three-fold increase increase
in the p21 luc activity when compared
with control (in the absence of BG) (Figure 4A).
Benzylguanine Recruits p53 to p21
Promoter and Induces p21 Expression
We have investigated the mechanistic
aspect of p21 induction by BG in tamoxifen-resistant MCF7 cells by ChIP assay.
BG enhances p53 recruitment to 5′ and 3′
sites of the p21 promoter (Figure 4B).
When p53 is knocked down by siRNA,

p53 recruitment to p21 promoter was decreased significantly (Figure 4B). The reduction in p21 expression in p53 knock
down cells was not reversed by the addition of BG (Figure 4C). These results suggest that BG induces p21 transcription
via p53.
Benzylguanine Inhibits TamoxifenResistant Breast Cancer Cell Growth
and Increases Resistant Breast
Cancer Cell Sensitivity to Antiestrogen
Therapy (TAM/ICI) In Vivo
Detailed necropsy revealed that all mice
had mammary tumors. The data summarized in Table 1 shows that daily BG alone
or in combination with twice weekly
TAM/ICI decreased median tumor volume and weight significantly, as compared with median volume and weight of
tumors seen in mice treated with single
agent TAM/ICI and as compared with
control mice. BG treatment alone led to
64% (P < 0.0001) reduction in the tumor
weight and 53% (P < 0.0001) reduction in
tumor volume compared with control
(Figure 5 and Table 1). The combination of

BG + TAM/ICI produced the greatest decrease with 76% and 71% in median
tumor volume as compared with control
mice: 62.0 mm3 (TAM + BG), (P <
0.0001)/75.1 mm3 (ICI + BG), (P < 0.0001)
versus 254.8 mm3 (control) (Figure 5 and
Table 1). Tumor weight was reduced significantly (87% in BG + TAM group and
77% in BG + ICI group) in mice treated
with combination therapy as compared
with control mice: 32.50 mg (TAM + BG),
(P < 0.0005) and 58.2 mg (ICI + BG), (P <
0.0005) versus 260.6 mg (control) (Figure 5
and Table 1). Body weight was not significantly different among treatment groups
and as compared with control mice. No
visible liver metastases were present (detection was done with the aid of a dissecting microscope) in all treatment groups.
IHC Analysis
Tumors harvested from all groups were
processed for routine histological and
IHC analysis. The BG and combination
treatment (BG + TAM/ICI) mediated, in
vivo, correlative effects on MGMT, ERα,
p53 and p21 were studied by IHC analy-
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Figure 5. Benzylguanine inhibits tamoxifen-resistant breast tumor growth and sensitizes resistant breast cancer cells to antiestrogen therapy. Mammary tumors were treated with a
single agent (TAM/ICI/BG) or with combination therapy (BG + TAM/ICI). Treatment effect
was measured by tumor volume and weight. BG either alone or in combination with
TAM/ICI significantly decreased breast tumor growth.

sis and quantified using the ImmunoRatio plugin as described in Materials and
Methods. Tumors from mice treated with
BG alone or combination (BG + TAM/ICI)
exhibited a significant decrease in MGMT
(53% decrease by BG alone, 81% decrease
by BG + TAM and 72% decrease by BG +
ICI when compared with control), ERα
(40% decrease by BG alone, 30% decrease
by BG + TAM and by 38% decrease by
BG + ICI when compared with control)
and ki-67 as compared with tumors
treated with TAM/ICI alone or control
group (Figure 6). p53 expression was not
altered significantly across groups (Fig-

ure 6). In sharp contrast, p21 expression
was increased significantly in tumors
from mice treated with BG alone or combination (BG + TAM/ICI) (Figure 6).
Benzylguanine Induces a Favorable
ERα Phosphorylation Phenotype with
High Ser167 and Low Ser118
Phosphorylation
Phosphorylation of ERα is triggered
by ligand binding, as well as by the action of several drugs. In our in vitro
phosphorylation experiments, we added
17β-estradiol (10 nmol/L) for 30 min
prior to harvesting the cells. There are
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various sites on the ERα protein that
can undergo phosphorylation (Ser167,
Ser104/106, Ser118) each bearing its
own functional significance. Phosphorylation at Ser167 correlates with increased
ERα sensitivity to tamoxifen and phosphorylation at Ser118, Ser104/106 and
Tyr537 is associated with functional impairment and tamoxifen resistance of
the ERα (61). In vitro analysis revealed
no phosphorylation at residues
Ser104/106 or Tyr537 after treatment
with BG or any of the combinations
used (BG + TAM/ICI) (Figure 7A). BG
alone or combination treatment (BG +
TAM/ICI) enhanced phosphorylation of
Ser167 (Figure 7A), supporting the BG
role in enhancing ERα sensitivity to
tamoxifen. We also have confirmed previous observations by others (62) that
tamoxifen alone induced Ser118 phosphorylation in tamoxifen-resistant cells,
already recognized as one of the mechanisms of acquired tamoxifen resistance
(Figure 7A). In this, in vitro, 48 h cell
culture model there is no significant decrease in the Ser118 phosphorylation
under the influence of BG. We also have
shown that silencing MGMT by other
mechanisms, such as by using MGMT
specific siRNA, also leads to phosphorylation of ERα at Ser 167 site correlating
with functional restoration of ERα, similar to the effect of BG-mediated MGMT
inhibition (Figure 7B).
IHC correlative quantified analysis of
ERα phosphorylated Ser167 and Ser118
was done using ImageJ/ImmunoRatio
plugin (Figure 7C), as described in Materials and Methods. In vivo, we have
found that phosphorylated Ser167 was
increased significantly in both BG alone
(28-fold increase) and combination treatment (BG + TAM/ICI: 90/80-fold increase), reaffirming the possible role of
BG in the functional restoration of the
ERα in tamoxifen-resistant breast cancer.
On the other hand, in vivo, there is significant reduction in the Ser118 phosphorylation in the groups treated with BG
alone (7.8-fold decrease versus control)
or combination treatment (BG +
TAM/ICI: 4.3/4-fold decrease versus
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Figure 6. Histology and IHC analysis. Mice with mammary tumors were treated with BG or tamoxifen or ICI, or combination therapy (BG +
TAM/ICI). The sections were immunostained for expression of MGMT, ERα, p53, p21 and ki-67. Tumors from mice treated with BG or combination
therapy had a significant decrease in the expression of MGMT, ERα and ki-67. p53 expression was not altered significantly in these treatment
groups. Expression of p21 was increased significantly in all treatment groups compared with controls. Representative samples (40×) are shown.
IHC correlative quantified expression analysis was done using ImageJ/ImmunoRatio plugin, as described in the Materials and Methods.

control) and, when compared with tamoxifen-only or ICI-only treated group,
the BG-mediated inhibitory effect of
Ser118 phosphorylation is even more significant (TAM/ICI: 11/9-fold). These results demonstrate that BG, either alone
or in combination with TAM/ICI, by
dual, differential, phosphorylation modulation of ERα (increasing Ser167 site
phosphorylation and inhibiting Ser118
phosphorylation) leads to a favorable
ERα site-specific phosphorylation phenotype known to correlate with a functional ERα and increased survival (7)
(Figure 7C). Furthermore, the phosphorylation ratio (PR) of phosphorylated

Ser167/phosphorylated Ser118 increases
exponentially under the influence of BG
and combination therapies—BG alone
(PR: 56-fold versus 0.25-fold control/
1.07-fold TAM only/1.2-fold ICI only)
versus BG + TAM/ICI (90-fold/80-fold)
(Figure 7C). All these findings, taken together, suggest that (BG via) MGMT inhibition reduces resistance to antiestrogen therapy through site-specific,
differential modulation of phosphorylation of ERα and may be a very effective
way of restoring ERα functional activity
given the favorable exponential increase
in the relative phosphorylation ratio
(Ser167/Ser118).

DISCUSSION
In this study, we describe a new facet
of the mechanism underlying tamoxifen
resistance, expanding on the observation that clinical tamoxifen resistance is
associated, in a small patient sample,
with increased MGMT expression (Figure 1). We support this observation by
showing that the already increased
MGMT expression in breast cancer cells
(Figure 2A) is further increased by prolonged exposure to tamoxifen both in
vitro and in vivo (Figures 2B and 6). Further, we show that inhibition of MGMT
in tamoxifen-resistant breast cancer cells
(MCF7) via either siRNA (Figure 2C) or
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Figure 7. Benzylguanine phosphorylates ERα at Ser167 site. Tamoxifen-resistant MCF7 breast cancer cells were treated in presence or absence
of BG (140 μmol/L) and 24 h later either TAM (1 μmol/L) or ICI (1 μmol/L) was added for another 48 h after treatment and 30 min prior to harvest 17β-estradiol (10 nmol/L) was added. Western blot analysis was performed. (A) BG either alone or in combination with antiestrogen therapy (TAM/ICI) significantly increased ERα Ser167 phosphorylation. [Control ( ); 4-OH TAM ( ); ICI ( ); BG ( ); 4-OHTAM + BG ( ); ICI + BG ( )].
(B) Inhibition of MGMT by specific siRNA led to similar increase in phosphorylation of ERα Ser 167. Mice with mammary tumors were treated
with BG or tamoxifen or ICI, or combination therapy (BG + TAM/ICI). The sections were immunostained for expression of phosphorylated ERα
Ser167 and phosphorylated ERα Ser118. [NT ( ); MGMT KD ( )]. (C) BG either alone, or in combination with tamoxifen or ICI, significantly increased ERα Ser167. Alternatively, phosphorylated of ERα Ser118 was decreased significantly. This dual action of increased ERα Ser167 phosphorylation and decreased ERα Ser118 phosphorylation suggests that BG and BG combination therapies may lead to functional restoration of
ERα in tamoxifen-resistant tumors. Representative samples (40×) are shown. IHC correlative quantified analysis of ERα phosphorylated Ser167
and Ser118 was done using ImageJ/ImmunoRatio plugin (C), as described in Materials and Methods. (p-ERα Ser 167 [n];p-ERα Ser 118 [n]).
Continued

BG (Figure 3A) leads to growth inhibition which correlates with release of
apoptotic markers and cell cycle arrest
(Figures 3D, E, F and Supplementary
Figure 2). These findings correlate
with BG- and combination-therapy
(BG + TAM/ICI)–induced tumor growth
inhibition as measured by volumes and
weights in our tamoxifen-resistant
breast cancer animal model (Figure 5).
There is increased p53 binding to the
p21 promoter after BG-induced MGMT

inhibition (Figure 4B). BG-mediated p21
induction relies on the presence of functional p53 (Figures 4A, B, C). We have
checked multiple phospho-p53 antibodies
and have not found any change in the
phosphorylation of p53 under the influence of BG. In our prior work 48 we have
described a mechanism of p53-induced
MGMT inhibition which did not rely on
activation via phosphorylation. We have
shown that restoration of specific p53
function (even in mutated p53 cell lines)
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did not require increased expression of
the gene or modulation of active, phosphorylated protein and have described a
new mechanism where p53-induced
MGMT inhibition relied entirely on the
increased binding of p53 to the MGMT
promoter via increased recruitment of the
HDAC1 and mSin3A corepressors (48).
We hypothesize that a similar mechanism
(not relying on activation via phosphorylation) is at play in this case where we
hypothesize there is a mutual corepres-
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Figure 7. Continued.

sor-based MGMT:p53 interaction which
does not rely on activation via phosphorylation of either p53 or MGMT. We suggest that, due to specific corepressor play,
MGMT modulates p53 activity/function,
and, in our system, suppressing MGMT
(via BG) improves p53 functional activity
which, in turn, improves ERα function.
There is an important observation we
want to make regarding the MGMT level
required for functional impairment of
p53. p53 function is essential to ERα expression (63–66). Mutations inactivating
p53 tend to be associated with an ERnegative breast cancer phenotype (64) and
a resistance to tamoxifen. Varying degrees
of p53 functional impairment are associated with high MGMT expression. In this
work, we show that worsening ERα functional impairment correlates with increasing MGMT levels, which are much higher
than the MGMT levels normally seen in

normal epithelial breast cells (Figure 2A).
Inhibition of MGMT in our model leading
to restoration of ERα function relies on
functional activation of p53 and is dependent on some degree of functional preservation of p53 activity. The relative MGMT
expression level (compared with normal
breast epithelial cells) seems to be relevant. In a setting where there is only mild
ER expression correlating with only mild
elevation of MGMT and there is significant preservation of mutated p53 function
as substantiated by only a mild elevation
of MGMT level (30%) (Figure 2A), as is
the case with the BT474 breast cancer cell
line, inhibition of MGMT does not lead to
any modulation of ERα and/or p53 (Figure 2E). This distinction brings out a relevant point, and, while we do not want to
generalize, our data suggests that high
levels of MGMT (1–3-fold higher than the
ones seen in the normal cell of origin) are

associated with a change in the regulatory
paradigm between p53 and MGMT,
where high levels of MGMT may impair
p53 function.
We also have found that BG-induced
growth inhibition, correlating with
proapoptotic and cell cycle regulatory
functions in ER negative cells (MDA MB
468, SKBR3 and HCC38) (data not
shown). There was further growth inhibition of tamoxifen-resistant cells (MCF7)
when TAM or ICI were added to BG (Figure 3B), suggesting that beyond the
proapoptotic and cell cycle regulatory actions of BG there is an additional growth
inhibitory mechanism relying on ERα. In
tamoxifen-resistant breast cancer cells
(MCF7), there is a direct correlation between MGMT and ERα, with inhibition
of MGMT correlating with ERα inhibition, while both inversely correlate with
p53 (Figure 2D).

MOL MED 18:913-929, 2012 | BOBUSTUC ET AL. | 927

MGMT INHIBITION REDUCES ANTIESTROGEN RESISTANCE

Our study further suggests that the
growth inhibition gains noted with the
combination treatment (BG versus
BG + TAM/ICI) may be due to a favorable phosphorylation phenotype shift
triggered by inhibition of MGMT (Figure 7C). We show that, in vivo, prolonged treatment with tamoxifen is associated with MGMT induction, which,
in turn, correlates with increased ERα
Ser118 (Figure 7C). We also show that,
alternatively, inhibition of MGMT leads
to partial suppression of ERα expression
(Figure 7B) and most importantly to
functional restoration of ERα sensitivity
to antiestrogens by inducing a favorable
phosphorylation phenotype (ERα with
low Ser118 and high Ser167 phosphorylation) (Figures 7B, C), known to correlate with increased sensitivity to antiestrogen therapy and increased survival
(7). Our gene array results suggest that
there is a shift under the influence of BG
in specific MAPK pathway-related isoforms which may differentially target
phosphorylation of Ser167 and Ser118
(data not shown). Our results also show
that the ratio of p-Ser167/p-Ser118 further increases with combination therapy,
when TAM/ICI are added to BG (Figure 7C), further supporting the claim of
a favorable ERα modulation as the massive decrease in the p-Ser118 and increase in p-Ser167 correlate with a functional ERα phenotype—with a
phosphorylation pattern closer to the
ligand binding driven phosphorylation
pattern (low Ser118 phosphorylation) as
opposed to the ligand independent,
MAPK driven, high Ser118 phosphorylation described with ERα resistance to
antiestrogens.
We also report that BG could lead to
both p53- and MGMT-dependent modulation of ERα function. The manner of
administration (continuous or intermittent) and the timing relative to when BG
(or alternative MGMT inhibitor) should
be introduced as an add-on to the antiestrogen therapy (early/late intermittent
versus late/early continuous) will have
to be further investigated in translational
models and clinical trials.

CONCLUSION
This study suggests that inhibition of
MGMT restores ERα functional sensitivity to antiestrogen therapy by inducing a
favorable shift in the ERα phosphorylation phenotype (high p-ERα Ser167/low
p-ERα Ser118).
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